Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Inflammatory Breast Cancer: early-phase trial registry
2 of 6 indexed Inflammatory Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Inflammatory Breast Cancer: 6 US clinical trials tracked, 2 recruiting.
Inflammatory Breast Cancer is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 2 of these trials.
Enrollment posture brief
Registry condition inflammatory-breast-cancer
OPEN 2 | RECR 33% | LATE 0 | EARLY 4 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Inflammatory Breast Cancer lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Inflammatory Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Inflammatory Breast Cancer is recruiting below its size-band peers.
2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Inflammatory Breast Cancer research.
Dana-Farber Cancer Institute accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Inflammatory Breast Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 67 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Inflammatory Breast Cancer research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Brigham and Women's Hospital
NCT04030507
Refining Local-Regional Therapy for IBC
Dana-Farber Cancer Institute
NCT04636710
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
NCT01525966
Onvansertib + Paclitaxel In TNBC
Antonio Giordano, MD
NCT05383196
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
NCT02623972
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
NCT00513695
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Inflammatory Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Inflammatory Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Inflammatory Breast Cancer page
6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Inflammatory Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Inflammatory Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Inflammatory Breast Cancer condition card totals 6 registered trials; most-linked intervention sunitinib malate; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.